Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodine-tositumomab for previously untreated follicular non-hodgkin lymphoma: SWOG S0016

Journal of Clinical Oncology

Volumn 31, Issue 3, 2013, Pages 314-320

  Press, Oliver W ^a,b   Unger, Joseph M ^a   Rimsza, Lisa M ^c   Friedberg, Jonathan W ^d   LeBlanc, Michael ^a   Czuczman, Myron S ^e,f   Kaminski, Mark ^g   Braziel, Rita M ^h   Spier, Catherine ^c   Gopal, Ajay K ^a,b   Maloney, David G ^a,b   Cheson, Bruce D ^f,i   Dakhil, Shaker R ^j   Miller, Thomas P ^c   Fisher, Richard I ^d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^j WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG FATALITY; DRUG INDUCED CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONSOLIDATION CHEMOTHERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; NEOPLASM STAGING; PREDNISONE; PROPORTIONAL HAZARDS MODELS; RADIOIMMUNOTHERAPY; VINCRISTINE;

EID: 84873397196     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.4101     Document Type: Article

References (35)

1. Press OW: Follicular lymphoma, in Kaushansky K, Lichtman M, Beutler E, et al (eds): Williams' Hematology (ed 8). New York, NY, McGraw-Hill Medical Publishing Division, 2009, pg 1565
2. Fisher RI, Le Blanc M, Press OW, et al: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:8447-8452, 2005
3. Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019-5026, 2005 (Pubitemid 46224008)
4. Liu Q, Fayad L, Cabanillas F, et al: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M. D. Anderson Cancer Center. J Clin Oncol 24:1582-1589, 2006 (Pubitemid 46638782)
5. Friedberg JW, Taylor MD, Cerhan JR, et al: Follicular lymphoma in the United States: First report of the national LymphoCare study. J Clin Oncol 27:1202-1208, 2009
6. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42-51, 2011
7. Press OW, Unger JM, Braziel RM, et al: A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 102:1606-1612, 2003 (Pubitemid 37022549)
8. Press OW, Unger JM, Braziel RM, et al: Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24:4143-4149, 2006 (Pubitemid 46622291)
9. Kaminski MS, Tuck M, Estes J, et al: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441-449, 2005 (Pubitemid 40175970)
10. Link BK, Martin P, Kaminski MS, et al: Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: Eight-year follow-up of a multicenter phase II study. J Clin Oncol 28:3035-3041, 2010
11. Zinzani PL, Rossi G, Franceschetti S, et al: Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin Cancer Res 16:3998-4004, 2010
12. Zinzani PL, Tani M, Fanti S, et al: A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol 19:769-773, 2008 (Pubitemid 351461050)
13. Jacobs SA, Swerdlow SH, Kant J, et al: Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 14:7088-7094, 2008
14. Morschhauser F, Radford J, Van Hoof A, et al: Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-5164, 2008
15. Witzig TE, Fishkin P, Gordon LI, et al: Treatment recommendations for radioimmunotherapy in follicular lymphoma: A consensus conference report. Leuk Lymphoma 52:1188-1199, 2011
16. Czuczman MS, Grillo-López AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999 (Pubitemid 29022402)
17. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005 (Pubitemid 41742196)
18. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005 (Pubitemid 40223656)
19. Marcus R, Imrie K, Solal-Celigny P, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579-4586, 2008
20. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992, 2007 (Pubitemid 46972781)
21. Salles G, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood 112:4824-4831, 2008
22. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
23. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
24. Cheson BD: Role of functional imaging in the management of lymphoma. J Clin Oncol 29:1844-1854, 2011
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
26. Cox DR: Regression models and life tables (with discussion). J Roy Statist Soc Serv B 34:187-220, 1972
27. Solal-Céligny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004 (Pubitemid 39166497)
28. 27a. Velasquez WS, Lew D, Grogan TM, et al: Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol 21:1996-2003, 2003 (Pubitemid 46606389)
29. Dana BW, Dahlberg S, Nathwani BN, et al: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993 (Pubitemid 23105672)
30. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
31. Pfreundschuh M, Trümper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
32. Bennett JM, Kaminski MS, Leonard JP, et al: Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine 131I tositumomab. Blood 105:4576-4582, 2005 (Pubitemid 40807274)
33. Witzig TE, White CA, Gordon LI, et al: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 21:1263-1270, 2003 (Pubitemid 46606402)
34. Vidal L, Gafter-Gvili A, Salles G, et al: Rituximab maintenance for the treatment of patients with follicular lymphoma: An updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 103:1799-1806, 2011
35. Martinelli G, Schmitz SF, Utiger U, et al: Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 28:4480-4484, 2010